The True Story Behind “Normal and Customary Rates” for Insurance Reimbursement

Andrew Cuomo, the Attorney General in New York State, just completed an agreement with a major medical insurer, which will create a fairer method to set reimbursement rates for medical treatment that has been obtained out of network. UnitedHealth Group, which is the nation’s second largest health insurer, has agreed to modify their system of [...]

Can the Prostate Cancer Community Finally Come Togrther?

Yesterday afternoon I participated in a conference call, which included representatives from most of the major prostate cancer organizations in the United States. Alvin Chin and John Willey who serve as consumer advocates for the Department of Defense Congressionally Directed Medical Research programs (DOD CDMRP) prompted the call. Alvin and John serve specifically on the [...]

Statins, Screening and Access to Health Care Have Led to Fewer Prostate Cancer Deaths

An editorial in today's edition of Urotoday, "Exploring Causes for Declining Prostate Cancer Mortality Rates in the United States" (1/5/09), looks at possible explanations for the the reduction in deaths from prostate cancer in recent years ('93-'03).  The authors relied on information from a a study reported recently in the journal Urologic Oncology (Nov-Dec). The researchers  [...]

By |2017-10-19T10:56:29-04:00January 5th, 2009|Advocacy, Other Treatments, Research Update|0 Comments

Who Should Become the New FDA Commissioner?

The Food and Drug Administration (FDA) is one of the major governmental entities that has a significant, direct and immediate affect on any of us who has any illness. All men with prostate cancer have had their life and their deaths impacted by the FDA. This impact has not been on just a few of [...]

Go to Top